Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 27:10.14309/ajg.0000000000002674.
doi: 10.14309/ajg.0000000000002674. Online ahead of print.

Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience

Jeffrey A Berinstein  1 , Taylor Karl  2 , Anish Patel  3 , Michael Dolinger  4 , Terrence A Barrett  5 , Waseem Ahmed  2 , Ben Click  2 , Calen A Steiner  2 , David Dulaney  3 , Jake Levine  1 , Syed Adeel Hassan  5 , Courtney Perry  5 , Deborah Flomenhoft  5 , Ryan C Ungaro  4 , Elliot M Berinstein  1 , Jessica Sheehan  1 , Shirley Cohen-Mekelburg  1   6 , Randolph E Regal  7 , Ryan W Stidham  1 , Shrinivas Bishu  1 , Jean-Frederic Colombel  4 , Peter D R Higgins  1
Affiliations

Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience

Jeffrey A Berinstein et al. Am J Gastroenterol. .

Abstract

Introduction: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy.

Methods: Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions.

Results: Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted.

Discussion: Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.

PubMed Disclaimer

References

    1. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5(1):103–110. doi: 10.1016/j.cgh.2006.09.033 - DOI - PubMed
    1. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330(26):1841–1845. doi: 10.1056/NEJM199406303302601 - DOI - PubMed
    1. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805–1811. doi: 10.1053/j.gastro.2005.03.003 - DOI - PubMed
    1. Govani SM, Berinstein JA, Waljee AK, Stidham RW, Higgins PDR, Hardiman KM. Use of Accelerated Induction Strategy of Infliximab for Ulcerative Colitis in Hospitalized Patients at a Tertiary Care Center. Dig Dis Sci. 2020;65(6):1800–1805. doi: 10.1007/s10620-019-05957-0 - DOI - PubMed
    1. Berinstein JA, Aintabi D, Higgins PDR. In-hospital management of inflammatory bowel disease. Curr Opin Gastroenterol. 2023;39(4):274–286. doi: 10.1097/MOG.0000000000000953 - DOI - PMC - PubMed

LinkOut - more resources